Authorization

Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Presentation will be held on Monday, September 12, 2022, from 10:30 a.m. to 11:00 a.m. EDTNEW HAVEN, Conn., Sept. 7, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvioa?? (oral nalbuphine ER) for the treatment of prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis (IPF), today announced that Jennifer Good, President and Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022, at 10:30 a.m. ET. Ms. Good, along with Lisa Delfini, Chief Financial Officer, will also participate in investor meetings with attendees.
Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
H.C. Wainwright 24th Annual Global Investment Conference (Hybrid)
Date: Monday, September 12, 2022
Company presentation: Jennifer Good, President and CEO
Time: 10:30 AM ETThe presentation will be available to attending participants. For more information about the H.C. Wainwright 24th Annual Global Investment Conference or to register in-person or virtual please visit: https://hcwevents.com/annualconference/
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Ноябрь 2022    »
ПнВтСрЧтПтСбВс
 123456
78910111213
14151617181920
21222324252627
282930